Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure? ∗
نویسندگان
چکیده
منابع مشابه
Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?
SEE PAGE 573 A n association between diabetes and the risk of heart failure has been seen in observational studies. The mechanism is undefined, and it remains unclear whether dipeptidyl peptidase (DPP)-4 this association is related to concomitantmedical problems associated with diabetes (e.g., ischemic heart disease, renal dysfunction, hypertension) or the direct effect of poorly controlled blo...
متن کاملCardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.
The cardiovascular safety of DPP4 inhibitors as a class, especially in regards to heart failure, has been questioned after the publication of first trials (SAVOR-TIMI 53 and EXAMINE) assessing the cardiovascular risks of DPP4 inhibitors alogliptin and sitagliptin in 2013. Although there were no increased risks in composite cardiovascular outcomes, the SAVOR-TIMI 53 trial reported a 27% increase...
متن کاملPlay of Chance Versus Concerns Regarding Dipeptidyl Peptidase-4 Inhibitors: Heart Failure and Diabetes.
The delicate balance of disease management versus off-target effects of treatment continues to be a vital concern to both patients and physicians. This article offers a brief overview of heart failure in diabetes and comments on the recent outcome trials of dipeptidyl peptidase-4 (DPP-4) inhibitors, with a closer look at a few pathobiological concerns. The importance of safe antidiabetic treatm...
متن کاملDiabetes and cardiovascular risk: are dipeptidyl peptidase-4 inhibitors beneficial?
Cardiovascular (CV) disease is a major cause of morbidity and mortality in patients with diabetes. Whereas the link between glycemic control and reducing microvascular disease is firmly established, the evidence for macrovascular risk reduction remains unclear. Despite a host of available drugs for lowering serum glucose, none to date have been shown to substantially reduce CV risk and some hav...
متن کاملAssociations of dipeptidyl peptidase‐4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus
BACKGROUND Heart failure (HF) and diabetes mellitus (DM) often co-exist. Treatment of DM in HF patients is challenging because some therapies for DM are contraindicated in HF. Although previous experimental studies have reported that dipeptidyl peptidase-4 (DPP-4) inhibitors improve cardiovascular function, whether DPP-4 inhibition improves mortality of HF patients with DM remains unclear. Ther...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JACC: Heart Failure
سال: 2014
ISSN: 2213-1779
DOI: 10.1016/j.jchf.2014.05.005